Showing 11 posts of 11 posts found.


Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

August 20, 2020
Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …


Biogen stock surges following patent victory over Mylan for Tecfidera

February 6, 2020
Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …


Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …


Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …


Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016
Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …

Biogen image

Pharma is boosting pipelines to avoid patent cliff

February 11, 2015
Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera

Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …

Genzyme image

FDA green lights Lemtrada for MS

November 17, 2014
Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera

The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …

Biogen image

FDA approves Biogen’s long-acting MS drug

August 18, 2014
Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

biogen idec image

Strong sales for Biogen Idec’s MS drug

October 29, 2013
Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera

Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …

Aubagio image

Aubagio approved in Europe

September 3, 2013
Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera

Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …

FDA image

US nod for Tecfidera

March 28, 2013
Sales and Marketing Biogen, FDA, tecfidera

The FDA has given Biogen Idec’s oral multiple sclerosis treatment Tecfidera the green light. Earlier this week Tecfidera (dimethyl fumarate) …

Latest content